Contents

30 June 2010
Vol 2, Issue 38
  • Contents

    • Editorial

      • Qualifying Therapeutic Discovery Project Tax Credit

        The U.S. Patient Protection and Affordable Care Act includes an opportunity for small life sciences companies to earn tax credits for research and development activities or exchange these credits for grants.

    • Commentary

    • Perspective

    • Research Articles

      • Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants

        Two patients with Parkinson’s disease, successfully treated with fetal tissue transplants more than a decade ago, developed troublesome involuntary movements, which could be treated with a serotonin receptor agonist.

      • Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients

        This study demonstrates the relation among structural genomic alterations, molecular subtype, and clinical behavior and shows that an objective score of genomic complexity can provide independent prognostic information in breast cancer.

    • Editors' Choice

      • Dark Matter Revealed

        Rare variants in the sialic acid acetylesterase gene result in substantial risk for common autoimmune conditions.

      • Going Organic Yields a Super Model System

        A new organ-on-a chip microdevice models the human alveolar-capillary interface—the key functional unit of the living lung—and mimics organ-level functions.

      • Sticks and Stones and Mending Bones

        Prevascularized bone grafts may speed up bone healing in trauma or fractures with serious complications.

    • Podcast

      • Science Translational Medicine Podcast: 30 June 2010

        A conversation with Gary L. Hecimovich and Victoria E. Boegh from Deloitte Tax LLP on the new $1 billion program created by the U.S. Patient Protection and Affordable Care Act.

About The Cover

Cover image expansion

ONLINE COVER Fertile Policy Fuels Innovation. The U.S. Patient Protection and Affordable Care Act (enacted on 23 March 2010) created a $1 billion program to award, on a competitive basis, federal subsidies to qualifying therapeutic discovery projects being conducted at small biomedical companies. In this week's Editorial and Podcast, Victoria E. Boegh and Gary L. Hecimovich, both from Deloitte Tax LLP, describe this unique opportunity for life sciences companies in the United States to earn tax credits for research and development activities or to exchange these credits for grants. [CREDIT: CHRIS BICKEL/SCIENCE TRANSLATIONAL MEDICINE]